This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PTCH1 / Protein patched homolog 1 · IHC design guide
Design Immunohistochemistry for PTCH1
Plan PTCH1 chromogenic IHC in paraffin sections using the observed cytoplasmic tissue pattern, while considering its membrane and ciliary localisation (HPA tissue IHC; UniProt). The IHC-validated antibody has a stated dilution range of 1:50–1:200; interpret staining cautiously because tissue evidence has uncertain concordance with RNA expression (datasheet; HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
PTCH1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic tissue staining (HPA tissue IHC); membrane and ciliary localisation (UniProt) | |
| Staining pattern | Cytoplasmic staining in most tissues (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | None in HPA (detected in all 45 tissues); use no-primary + isotype controls |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A00441) | |
| Caveat | Staining has uncertain concordance with RNA expression (HPA tissue IHC) | |
| Regulation | Hedgehog may alter ciliary PTCH1 (UniProt) | |
| Isoform / epitope | 4 isoforms; check whether the epitope is extracellular or cytoplasmic (UniProt) |
Section 1
Recommended PTCH1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published PTCH1 staining protocols for breast carcinoma (PMC2633285), rat cartilage (PMC4377216), and pancreatic tumor tissue (PMC4085644).
| Sample | Paraffin-embedded human breast carcinoma tissue; fixative not specified (datasheet A00441) |
| Fixation | Image fixative and duration unreported (datasheet A00441); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-PTCH1, 1:50-1:200 (datasheet A00441) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | PTCH1-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic expression in most tissues. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 HIER at 95–98 °C for 20 min (page retrieval rule); optimize with tissue controls.
Section 2
What Is the Expected PTCH1 Staining Pattern?
PTCH1 is a 12-pass membrane protein at the cell membrane and primary cilium (UniProt Q13635 topology; UniProt Q13635 subcellular location). In tissue IHC, HPA describes predominantly cytoplasmic staining and reports high staining in selected glandular, hematopoietic, neuronal and endothelial cells (HPA tissue IHC). Treat that distribution as a reference pattern, not definitive validation: HPA rates its tissue staining Uncertain because antibody staining and RNA expression show low consistency (HPA tissue IHC).
| Distinct staining in glandular cells of adrenal gland, appendix or breast, or hematopoietic cells in bone marrow (HPA tissue IHC). | These are reported high-staining cell populations (HPA tissue IHC). Score the relevant cells and their compartment, rather than calling an entire section positive from isolated color (general IHC practice). HPA's Uncertain reliability limits how strongly a match confirms PTCH1 (HPA tissue IHC). |
| Cytoplasmic staining in an expected cell population, with or without a discernible membrane rim (HPA tissue IHC; UniProt Q13635 subcellular location). | Cytoplasmic staining matches HPA's tissue IHC profile, while a membrane-associated component is compatible with UniProt localization (HPA tissue IHC; UniProt Q13635 subcellular location). Routine tissue IHC cannot establish primary-cilium localization from broad cytoplasmic color alone (general IHC practice). |
| Predominantly nuclear staining, with no convincing cytoplasmic or membrane-associated pattern (HPA tissue IHC; UniProt Q13635 subcellular location). | Neither source places PTCH1 in the nucleus (HPA tissue IHC; UniProt Q13635 subcellular location). Investigate a compartment mismatch as possible nonspecific staining or detection artefact before interpreting it as PTCH1 (general IHC practice). |
| Strong color in a cell population outside the reported pattern, especially when expected cells remain unstained (HPA tissue IHC). | The mismatch raises possible cross-reactivity or endogenous detection activity; it does not identify which occurred (general IHC practice). HPA lists low staining in smooth muscle cells and soft-tissue fibroblasts, but supplies no negative-tissue list (HPA tissue IHC). |
| Diffuse color across cells and surrounding tissue, or no staining in an HPA high-staining reference population (HPA tissue IHC). | Diffuse color weakens compartment and cell-type interpretation; absent reference staining may reflect an assay failure or a biological/sample difference (general IHC practice). Neither result alone resolves specificity, particularly with HPA's Uncertain tissue reliability (HPA tissue IHC). |
💡Expected PTCH1 appearanceCall a result plausible when defined expected cells show discernible cytoplasmic staining, potentially with membrane-associated signal, and an HPA high-staining reference shows stronger staining than background; widespread haze or isolated nuclear color is suspect (HPA tissue IHC; UniProt Q13635 subcellular location; general IHC practice).
| Tissue evidence quality (HPA tissue IHC) | HPA calls tissue staining Uncertain because antibody staining and RNA expression have low consistency; its high-staining examples guide comparison but do not prove specificity in a new specimen (HPA tissue IHC). |
| Membrane topology and antibody access (UniProt Q13635 topology) | PTCH1 has 12 transmembrane segments plus extracellular and cytoplasmic regions (UniProt Q13635 topology). Without the antibody epitope, topology alone cannot specify a retrieval or permeabilisation setting (general IHC practice). |
| Isoform coverage (UniProt Q13635 isoforms) | UniProt lists 4 isoforms: L, L′, M and S (UniProt Q13635 isoforms). Their presence does not show which isoforms an unspecified antibody recognizes; interpret tissue differences without assuming universal isoform detection (general IHC practice). |
| Glycosylation and processing (UniProt Q13635 features) | Six glycosylation sites are annotated, and the listed protein chain spans residues 1–1447 with no signal peptide or propeptide (UniProt Q13635 features). These annotations alone do not establish epitope masking, shedding or fixation sensitivity (general IHC practice). |
| Primary-cilium context (UniProt Q13635 subcellular location) | PTCH1 localizes to the primary cilium and delocalizes after hedgehog binding, according to UniProt (UniProt Q13635 subcellular location). Therefore, absence of a visible ciliary punctum in paraffin IHC should not override an otherwise interpretable cell pattern (general IHC practice). |
| IF/ICC Q&A (HPA subcellular) | Q: What pattern is reported for IF/ICC? A: Mainly Golgi apparatus, with additional primary-cilium localization; HPA marks both locations Approved (HPA subcellular). This is an IF/ICC observation, not a paraffin-IHC protocol or required slide pattern (HPA subcellular; general IHC practice). |
| Situation | Likely cause | Next action |
|---|---|---|
| Expected cells show only faint or absent staining despite an HPA high-staining reference choice (HPA tissue IHC). | An ineffective assay step or sample-specific expression difference is possible; HPA's high designation does not guarantee every specimen will stain (HPA tissue IHC; general IHC practice). | Check the validated IHC-P instructions for retrieval, antibody dilution and detection, and review the run's control section before changing interpretation (general IHC practice). |
| A uniform brown haze obscures cell borders and compartments (general IHC practice). | Excess chromogen development, insufficient blocking or overly concentrated antibody can elevate background (general IHC practice). | Compare with a reagent-omission control; review blocking, washes, dilution and development time under the chosen chromogenic workflow (general IHC practice). |
| Brown signal follows blood-rich or unrelated cells when HRP detection is used (general IHC practice). | Endogenous peroxidase activity can contribute color in an HRP-based assay, so the signal may not reflect antibody binding (general IHC practice). | Inspect an antibody-omission control and verify that the protocol's peroxidase-blocking step was performed effectively (general IHC practice). |
| Nuclear color dominates while expected cytoplasmic staining is unclear (HPA tissue IHC). | This compartment conflicts with HPA tissue IHC and UniProt localization; nonspecific staining or detection artefact is plausible (HPA tissue IHC; UniProt Q13635 subcellular location; general IHC practice). | Review controls and antibody concentration, then require a reproducible expected-cell pattern before scoring PTCH1 positivity (general IHC practice). |
| Smooth muscle cells or soft-tissue fibroblasts stain more strongly than the chosen reference population (HPA tissue IHC). | HPA reports low staining in those cells; cross-reactivity, endogenous detection activity or specimen variation could explain a reversal (HPA tissue IHC; general IHC practice). | Compare matched controls and the reported cell distribution, then record the discrepancy rather than treating those cells as a validated positive reference (HPA tissue IHC; general IHC practice). |
| No discrete ciliary signal is visible in a paraffin section (general IHC practice). | A cilium may be hard to resolve in routine chromogenic sections, and PTCH1 can leave the cilium after hedgehog binding (UniProt Q13635 subcellular location; general IHC practice). | Assess the overall cell and compartment pattern for IHC; use the separate IF/ICC guide if resolving Golgi or ciliary localization is the experimental goal (HPA tissue IHC; HPA subcellular; general IHC practice). |
Experiment evidence
IHC & IF images showing PTCH1 staining
A00441 · IHCImmunohistochemistry (IHC) analyzes of Patched (A2) pAb in paraffin-embedded human breast carcinoma tissue at 1:50.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000185920-PTCH1/tissue/cerebral+cortex#imid_3405108
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000185920-PTCH1/tissue/colon#imid_3401326
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000185920-PTCH1/tissue/liver#imid_3401335
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000185920-PTCH1/tissue/kidney#imid_3401328
HPA · ICC-IF HaCaTHuman Protein Atlas immunofluorescence, HaCaT, antibody HPA075072; green = PTCH1, blue = nucleus, red = microtubules.
HPA · ICC-IF HaCaTHuman Protein Atlas immunofluorescence, HaCaT, antibody HPA075072; green = PTCH1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for PTCH1 IHC & IF
🧪Run breast first and expect staining in glandular cells (HPA: High in breast glandular cells). HPA lists no negative tissue because PTCH1 is detected in all 45 scored tissues (HPA); use no-primary and isotype controls as the negative reference, and expect cells without specific staining on the positive slide to remain at background rather than assigning them a known PTCH1-negative identity.
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: None in HPA: PTCH1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show PTCH1 in HaCaT, Rh30, U2OS, ASC52telo, RPTEC/TERT1, hTERT-RPE1 (serum starved), with annotated localisation: Golgi apparatus (approved) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control, an isotype control matched to the primary antibody’s host species and clonality, and PTCH1-knockout material or a peptide-blocking control if available (standard IHC practice). On breast sections, check endogenous peroxidase background and, if using avidin–biotin detection, endogenous biotin before interpreting glandular staining (standard IHC practice).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported in the supplied evidence; the selected A00441 paraffin-section breast carcinoma caption reports 1:50 but leaves the fixative unreported (selected IHC caption). Antigen-retrieval dependence and whether frozen sections or IF are easier are unreported, so retrieval conditions require empirical optimization (supplied target/application evidence). No breast-specific artefact is documented here; assess staining against the background controls, while recognizing that PTCH1 can localize to the cell and cilium membranes (UniProt Q13635 localization).
HPA tissue IHC evidence for PTCH1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Low consistency between antibody staining and RNA expression data. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Appendix | Glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | Glandular cells | High | Protein (IHC) | HPA → |
| Caudate | Neuronal cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| None in HPA: PTCH1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead. | ||||
Section 3
Advanced PTCH1 IHC Tips
Troubleshoot PTCH1 staining in paraffin sections by checking retrieval, compartment, controls and scoring before interpreting signal.
How should I optimize antigen retrieval when PTCH1 staining is weak?
Start with citrate pH 6.0 HIER at 95–98 °C for 20 min (page retrieval rule: cytoplasmic / membrane antigen). Keep section thickness, cooling and detection conditions constant while comparing retrieval times, so a change in staining has one likely cause (standard IHC practice). PTCH1 has 12 transmembrane segments and extracellular as well as cytoplasmic regions, but the catalog antibody’s epitope is unspecified here (UniProt Q13635 topology; supplied product evidence). If staining remains weak, trial an alternative retrieval buffer on matched sections and judge improvement against background and tissue morphology (standard IHC practice).
Can fixation explain absent PTCH1 staining in paraffin sections?
PTCH1-specific fixation sensitivity is unknown from the supplied evidence; the selected A00441 image describes paraffin-embedded breast carcinoma at 1:50 but does not state a fixative (A00441 caption). Record the fixative, fixation duration and processing history for each specimen before comparing staining across cases (standard IHC practice). For a controlled troubleshooting run, process matched specimens consistently and compare the same retrieval and antibody conditions on each section (standard IHC practice). Interpret a negative result cautiously if fixation histories differ, because the image caption cannot establish how this antibody performs after any particular fixation regimen (A00441 caption; standard IHC practice).
Should PTCH1 appear at the membrane, cilium or inside cells?
Assess staining in its cellular context: PTCH1 is assigned to the cell membrane and primary cilium membrane (UniProt Q13635 subcellular location). Independent subcellular imaging places it mainly at the Golgi apparatus and additionally at the primary cilium, while tissue IHC reports broadly cytoplasmic staining with uncertain reliability (HPA subcellular; HPA tissue IHC). In chromogenic sections, examine whether signal follows a plausible cell boundary or intracellular pattern across intact cells, rather than relying on a single dark focus (standard IHC practice). If compartment calls matter, compare matched sections with an appropriate cell or cilium marker and document the compartment scored (standard IHC practice).
Could PTCH1 isoforms or epitope position change what I detect?
PTCH1 has 4 reported isoforms, L, L′, M and S, so establish which sequence the antibody recognizes before assigning isoform specificity (UniProt Q13635 isoforms; standard IHC practice). The protein has multiple extracellular loops and cytoplasmic regions separated by 12 transmembrane segments; epitope position therefore matters when interpreting accessibility (UniProt Q13635 topology). Extracellular sites at residues 141, 312, 349, 414, 875 and 1000 are annotated glycosylation sites, but this payload does not establish an effect on staining (UniProt Q13635 glycosylation). Request the catalog antibody’s immunogen or epitope information, then compare mapped sequence coverage across isoforms before interpreting discordant cases (standard IHC practice).
How can I check PTCH1 localisation by multiplex IF?
For the separate IF/ICC workflow, pair PTCH1 with a marker identifying the cells being assessed; glandular cells are reported as high in breast tissue IHC, although that tissue profile has uncertain reliability (HPA tissue IHC). Add a cilium marker when testing the primary cilium assignment, and acquire single-stain controls before interpreting overlap (HPA subcellular; standard IF practice). Choose a red or far-red PTCH1 channel after checking the specimen’s autofluorescence, particularly if green background obscures fine structures (standard IF practice). Set permeabilisation according to whether the verified epitope lies in a cytoplasmic region or an extracellular loop, and document the fixation used for IF (UniProt Q13635 topology; standard IF practice).
What controls help distinguish PTCH1 signal from chromogenic background?
Run a no-primary control through the same peroxidase and DAB steps to identify detection-system background, including endogenous peroxidase signal (standard IHC practice). Apply a peroxidase block and assess whether residual colour clusters in tissue compartments that stain without primary antibody (standard IHC practice). Compare the catalog antibody at the captioned 1:50 dilution with a titration on matched sections, keeping retrieval and development time fixed (A00441 caption; standard IHC practice). Treat broad cytoplasmic staining cautiously because the HPA tissue profile describes that pattern but rates its antibody staining versus RNA consistency as uncertain (HPA tissue IHC).
How should I score PTCH1 in heterogeneous tissue sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and compartment before scoring; PTCH1 is assigned to membrane and cilium locations, while tissue IHC reports cytoplasmic staining with uncertain reliability (UniProt Q13635 subcellular location; HPA tissue IHC). For a chromogenic readout, report percentage of positive viable cells and intensity, or calculate an H-score from intensity categories 0–3, yielding 0–300 (standard IHC practice). Normalize cell counts to the number of evaluable cells, or positive-cell density to viable tissue area in mm² (standard IHC practice). Hold thresholds, compartment rules and imaging settings constant across cases, and exclude necrotic or damaged regions from the denominator (standard IHC practice).
What makes a PTCH1-positive IHC result convincing?
A convincing result shows reproducible staining in intact cells with a documented compartment, supported by a clean no-primary control and consistent processing (standard IHC practice). PTCH1 has membrane and primary cilium assignments, while Golgi localisation is also reported; diffuse cytoplasmic tissue staining alone deserves caution because HPA rates its tissue IHC reliability uncertain (UniProt Q13635 subcellular location; HPA subcellular; HPA tissue IHC). Check whether apparent positivity is concentrated at section edges, in necrosis or in the no-primary control, where artefact can mimic DAB signal (standard IHC practice). Do not infer Hedgehog pathway activation from PTCH1 colour alone; PTCH1 regulates SMO, and staining measures protein detection rather than pathway activity (UniProt Q13635 function; standard IHC practice).
Boster reagents
Best PTCH1 / Protein patched homolog 1 IHC Antibodies
The catalog antibody has pictured PTCH1 IHC in human paraffin sections (catalog IHC image caption). It lists Human, Mouse and Rat reactivity, with no IF image (catalog reactivity; catalog IF image alts).
Real IHC data
Anti-Patched (A2) PTCH1 Antibody
Cat # A00441
A00441 will render with an IHC image of paraffin-embedded human breast carcinoma tissue at 1:50 (catalog IHC image caption). Its listed applications are IHC and WB, and its listed reactivity is Human, Mouse and Rat (catalog applications; catalog reactivity).
Which to pick: Choose A00441 for paraffin-section IHC: its own caption shows human breast carcinoma tissue at 1:50, but does not report the fixative (catalog IHC image caption). No IF/ICC choice is supported by this payload: A00441 has no listed IF application or IF image (catalog applications; catalog IF image alts). For cross-species work, A00441 lists Human, Mouse and Rat reactivity, although the pictured IHC result is human only (catalog reactivity; catalog IHC image caption).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q13635 (PTC1_HUMAN, Protein patched homolog 1).
- Human Protein Atlas. PTCH1 tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. PTCH1 subcellular location (ICC-IF): Mainly localized to the Golgi apparatus. In addition localized to the primary cilium..
- Human Protein Atlas. PTCH1 antibody validation summary (2 antibodies).
- Alterations in candidate genes PHF2, FANCC, PTCH1 and XPA at chromosomal 9q22.3 region: pathological significance in early- and late-onset breast carcinoma. Molecular cancer 2008 — PMC2633285.
- Expression of hedgehog signal pathway in articular cartilage is associated with the severity of cartilage damage in rats with adjuvant-induced arthritis. Journal of inflammation (London, England) 2015 — PMC4377216.
- miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1. Journal of experimental & clinical cancer research : CR 2014 — PMC4085644.
- Evaluation of Patched-1 Protein Expression Level in Low Risk and High Risk Basal Cell Carcinoma Subtypes. Asian Pacific journal of cancer prevention : APJCP 2019 — PMC6976826.
- PubMed PMID:8658145 — UniProt-cited evidence.
- PubMed PMID:8647801 — UniProt-cited evidence.
- PubMed PMID:15164053 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for PTCH1 (Protein patched homolog 1). Expected localisation Cytoplasmic tissue staining (HPA tissue IHC); membrane and ciliary localisation (UniProt). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A00441 at 1:50-1:200 (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative None in HPA (detected in all 45 tissues); use no-primary + isotype controls. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast carcinoma tissue; fixative not specified (datasheet A00441); 2. Fixation: Image fixative and duration unreported (datasheet A00441); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-PTCH1, 1:50-1:200 (datasheet A00441); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across paraffin sections (standard IHC practice; not target-specific); Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A00441); Caveat: Staining has uncertain concordance with RNA expression (HPA tissue IHC); Isoform / epitope: 4 isoforms; check whether the epitope is extracellular or cytoplasmic (UniProt); Regulation: Hedgehog may alter ciliary PTCH1 (UniProt). Evidence: UniProt Q13635, HPA tissue IHC · Uncertain, HPA ICC-IF · Mainly localized to the Golgi apparatus. In addition localized to…, Datasheet A00441, PMC2633285, PMC4377216. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/PTCH1/immunohistochemistry-ihc-guide.